Filing Flows › Aclaris Therapeutics (ACRS) › Q3 2026
Aclaris Therapeutics (ACRS) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Aclaris Therapeutics (ACRS) reported revenue of $1.5M for the third quarter 2026 (Q3 2026), -55% from a year earlier and -9% from the quarter before.
Aclaris Therapeutics, Q3 2026: revenue $1.5M (-55% year over year), net loss $18.5M, operating cash flow −$24.1M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.5M | -9% | -55% |
| Operating profit | −$21.3M | — | — |
| Net earnings | −$18.5M | — | — |
| Operating cash flow | −$24.1M | — | — |
What changed
Revenue was $1.5M in Q3 2026, down 55% year over year and down 9% from the previous quarter. Licensing was the largest line at 80% of revenue. Licensing lost $1.6M year over year (down 58%), 90% of the total change.
Operating costs exceeded revenue by $21.3M, an operating margin of -1441.2%. Total costs grew 12% against a revenue fall of 55%. The fastest-growing cost line was General & admin (+24%). The quarter ended with a net loss of $18.5M, narrower than the previous quarter's $21.5M loss.
Operating cash flow was −$24.1M. Non-cash charges added back $100K of depreciation and amortization and $3.0M of share-based compensation. Working capital and other items used $8.7M. Capital expenditures of $13K exceeded it, leaving free cash flow of −$24.1M.
Questions
What was Aclaris Therapeutics' revenue in the third quarter 2026?
Aclaris Therapeutics (ACRS) reported revenue of $1.5M for the third quarter 2026 (Q3 2026), -55% from a year earlier and -9% from the quarter before.